2013
Updates in therapy for uterine serous carcinoma
Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaSerous carcinomaTreatment of USCPaclitaxel-resistant diseasePI3/Akt/mTOR pathwayClass III β-tubulinEarly-stage diseaseNew target antigensAKT/mTOR pathwayVascular endothelial growth factorDistinct molecular pathogenesisHER2/neuIII β-tubulinCurrent clinical approachesEndothelial growth factorNovel microtubule-stabilizing agentEndometrial cancerAggressive variantOptimal therapyProspective studyPathway aberrationsClinical investigationSmall molecule inhibitorsTarget antigenClinical approach
2002
Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer
Cannon MJ, O’Brien T, Underwood LJ, Crew MD, Bondurant KL, Santin AD. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. Expert Review Of Anticancer Therapy 2002, 2: 97-105. PMID: 12113075, DOI: 10.1586/14737140.2.1.97.Peer-Reviewed Original ResearchConceptsDendritic cell-based immunotherapyCell-based immunotherapyPowerful antigen-presenting cellsPrimary T cell responsesDendritic cell vaccinationT cell responsesOvarian tumor antigenTumor-specific target antigensAntigen-presenting cellsTumor-specific antigensEffective immune responseCell vaccinationDendritic cellsMalignant diseaseOvarian cancerImmune responseTumor antigensTarget antigenImmunotherapyAntigenNovel targetVaccinationRecent recognitionCellsTumors